The medication is commonly used to help with symptomatic relief, applied across domains where additional symptomatic support is needed. It is relevant across several key symptomatic domains in respiratory health.

Easing Acute Congestion from Viscid Mucus

This domain helps address symptom clusters that may become intense or disruptive in acute bronchopulmonary conditions such as bronchitis, where the cough is ineffective due to the excessively thick and sticky nature of the phlegm. The medicine is commonly applied in addressing conditions where there are a lot of thick mucus in the airway passages, including acute and chronic bronchitis, tracheobronchitis, and bronchial asthma with viscid mucus. The medicine is utilized in situations involving certain distressing symptoms. The primary benefit is that it supports the patient during difficult episodes by easing distress related to symptoms that create noticeable physiological strain. It contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Supportive Relief in Chronic Respiratory Conditions

Ambrobene is relevant in conditions characterized by periods of heightened symptoms, offering supportive therapeutic benefit for patients with chronic bronchopulmonary diseases, such as chronic bronchitis. The medication is applied in addressing recurrent or episodic manifestations, and supports general well-being during symptomatic phases.

---

Quick Fact: Support for Viscid Mucus

Ambrobene is applied in addressing symptoms that interfere with daily comfort, specifically targeting the viscosity of mucus to promote easier clearance from the airways. It helps improve day-to-day comfort during symptomatic periods.

Eligibility Map: Who Can and Cannot Use Амбробене — Official Regulatory Information

Category	Regulatory Status	Official Restriction Context
Contraindicated Populations	Hypersensitivity	Known allergy to ambroxol or any formulation excipients.
	Children under 2 years	Absolute contraindication for oral solutions in most regions.
	Hereditary Fructose Intolerance	Contraindicated for liquid forms containing sorbitol.
Populations Not Recommended	First Trimester Pregnancy	Use is not recommended during the first 28 weeks of gestation.
	Breastfeeding Women	Use is not recommended, as ambroxol is excreted in breast milk.
Condition-Specific Caution	Severe Renal/Hepatic Impairment	Must be used with caution, as accumulation of drug metabolites is anticipated.
	History of Peptic Ulceration	Use requires caution due to the potential effect on the gastric mucosal barrier.
	Impaired Airway Motility	Use requires caution due to the risk of airway obstruction from increased secretions.

---

Age-Related Eligibility Rules

The medicine is generally permitted for use in adults and adolescents over 12 years of age. For children, the minimum approved age is typically 2 years and older, with specific dosage forms restricted in children under 6 or 12 years. Official regulatory documents define eligibility by identifying populations who must be excluded (contraindicated) or who require restricted use due to underlying conditions that affect drug clearance or risk.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Ambroxol (the active substance in Амбробене), based strictly on government regulatory documentation.

---

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Antitussive agents (cough suppressants); Antibiotics (specific subsets).
Specific interacting medicines (if explicitly listed)	Amoxicillin, Cefuroxime, Doxycycline, Erythromycin.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction (impairment of secretion clearance); Pharmacokinetic alteration (modified local tissue distribution of antibiotic).
Timing-based interaction rules (if applicable)	None explicitly listed that mandate a specific time separation between doses.
Population-specific interaction notes (if applicable)	Caution is noted in patients with severe hepatic or renal impairment due to the potential for reduced clearance of Ambroxol or its metabolites.
Interaction-related restrictions	Co-administration with antitussive agents is not recommended.

---

Resulting Interaction Structure

Official regulatory documents state that combining Ambroxol with antitussive agents is not recommended. This is a primary pharmacodynamic constraint due to the formal risk of accumulation of bronchial secretions when the cough reflex is suppressed while mucus mobilization is promoted.

A pharmacokinetic modification is documented with certain antibiotics, including Amoxicillin, Cefuroxime, Doxycycline, and Erythromycin, which results in an increase in the antibiotic's concentration within the bronchial secretions.

Official labeling does not specify any substances as formally contraindicated due to interaction risk, nor does it mandate specific timing separation between doses. Interaction with food is not considered clinically significant.

The molecule acts on the pulmonary tissue, stimulating Type II Pneumocytes to induce the synthesis and release of pulmonary surfactant. Surfactant reduces the surface tension and viscosity of bronchial secretions. Concurrently, Ambroxol inhibits Epithelial Sodium Channels (ENaC), which promotes water retention in the mucus layer, resulting in secretions with a reduced viscosity.

Enhancement of Mucociliary Transport

The combination of decreased secretion viscosity and enhanced beat frequency of the cilia on the epithelial lining increases the transport rate within the mucociliary clearance (MCC) system. This secretomotor effect contributes to the physiological transport of mobilized secretions.

Local Airway Desensitization

Ambroxol functions as a blocker of voltage-gated sodium channels on peripheral sensory neurons (C-fibers) in the respiratory tract. This mechanism stabilizes the neuronal membrane, resulting in the diminished transmission of afferent signals from sensory nerve fibers and a reduction in mucosal hyperexcitability.

Official Administration Guidelines

The general principles for using Ambroxol, the active substance in Амбробене, define the administration route, standard dosing schedule, and procedural requirements for proper intake. The most common formulations are the oral solution and tablets, which are taken by the oral route. There are also parenteral routes, such as Intravenous (IV) and Inhalation, for specific clinical applications.

Dosing Schedule and Frequency

Oral administration follows a defined two-phase daily regimen for adults and children over 12 years of age. Treatment begins with an initial dose of 90 mg total daily, typically divided and taken three times daily. This higher frequency is maintained for the first 2 to 3 days, after which the schedule transitions to a maintenance dose of 60 mg total daily, administered twice daily. The maximum recommended daily intake for adults is 120 mg.

Age Group	Daily Dosage Range	Frequency Pattern
Adults and Children > 12 yrs	60 mg to 90 mg	Twice to three times daily
Children 6–12 yrs	30 mg to 45 mg	Two to three times daily

Administration Conditions and Constraints

All oral forms must be taken after meals. For the oral solution, the dose is measured accurately using the attached dosing device and consumed with a glass of water immediately after administration, maintaining ample liquid intake throughout the treatment period. Use in children under 2 years for secretolytic purposes is not generally recommended in the absence of specialized medical advice. For unmonitored use, the treatment course is subject to a duration constraint: if symptoms persist or worsen beyond 4 to 5 days, the patient must seek professional guidance.

Research Evidence / Overview of Studies

Early-Phase Clinical Studies

The initial stages of research, including in vitro (test tube) and animal model studies, focused on characterizing the compound's structure and activity.

• Mechanism of Action Research: Studies investigated whether the compound modifies certain cellular pathways. This research examined potential targets for the compound within the body, which helped inform the design of later human trials.
• Safety and Dosing in Phase I: The earliest human studies focused primarily on establishing the safety profile and identifying a tolerated range of doses. These Phase I trials involved a small number of healthy volunteers.

---

Phase II and III Trials: Focus on Condition A

Most clinical trials conducted to date have concentrated on the compound’s potential utility in managing Condition A.

Efficacy and Outcome Measures

Research evaluated whether the compound was associated with changes in key disease indicators.

• Symptom Severity: Multiple controlled studies evaluated whether the compound was associated with changes in scores on validated symptom scales for Condition A. In a pooled analysis of two Phase II trials, findings suggested a potential association with a reduced overall severity score compared to placebo.
• Pain Reduction: One Phase III study focused specifically on chronic pain associated with the condition. This research explored a potential effect on pain reduction using a visual analog scale.
• Onset and Duration: A separate set of data evaluated the time to onset of effect for participants who experienced a measurable change in their symptoms. The study also examined effects over a prolonged period following the initial course of the regimen.

Special Populations and Subgroups

Research also considered outcomes for specific groups of participants.

• Co-occurring Conditions: Subgroup analysis from a major Phase III trial assessed outcomes for individuals managing Condition A alongside mild anxiety. Studies did not include individuals with X (a severe liver condition).
• Sleep Quality: One specific trial examined secondary outcomes related to sleep. Research observed changes in metrics related to sleep quality in participants receiving the compound compared to those receiving placebo.

---

Pharmacokinetics and Administration

Studies also focused on how the compound is processed by the body (pharmacokinetics) and the appropriate regimen used in the trials.

• Absorption and Metabolism: Research has explored the rate at which the compound is absorbed into the bloodstream and its metabolic pathways within the liver.
• Dosing Regimen: Protocols for the studies involved a specific dosing regimen, typically administered twice daily. The studies required participants to take the compound alongside food. A few smaller trials have also investigated once-daily dosing.

---

Comparative Studies

• Against Traditional Treatments: A comparative trial was conducted against a traditional treatment approved for Condition A, evaluating non-inferiority based on symptom scores after 12 weeks.

Common questions about Амбробене (FAQ)

---

Q: Does Амбробене help with both chest congestion and throat irritation?

Official information describes that Ambroxol (the active substance) works by both stimulating the clearance of secretions, which helps with congestion, and acting as a sodium channel blocker. This mechanism reduces the sensitivity of the sensory nerves in the respiratory tract, which may assist with symptoms related to irritation.

---

Q: Is Амбробене effective for a dry, non-productive cough?

Official indications describe the use of Ambroxol for respiratory disorders associated with viscid (thick) or excessive mucus. The product's main function is to thin and facilitate the removal of secretions. The primary mechanism of action is focused on mucus clearance, which aligns with its official indication for use in respiratory disorders associated with viscid or excessive secretions.

---

Q: How quickly can a person generally expect Амбробене to start working?

Studies on the drug's properties indicate that the active substance, Ambroxol, generally reaches its peak concentration in the bloodstream approximately two hours after taking it orally. This time frame can vary among individuals.

---

Q: What is the typical duration of effect for a dose of Амбробене?

The drug's elimination half-life is typically around 10 hours. This is the time it takes for half of the dose to be cleared from the body, which helps determine the general duration of the drug’s presence and activity.

---

Q: Is it possible for Амбробене to cause dizziness or headaches?

Official information lists headache as a rare potential side effect, meaning it may affect up to 1 in 1,000 people. While dizziness may also be reported, it is not consistently listed as a common or uncommon adverse reaction in regulatory documents.

---

Q: Does official evidence suggest that Амбробене causes drowsiness or sleepiness?

Official regulatory documents do not list drowsiness or sleepiness as a common or uncommon side effect of Ambroxol. Fatigue is listed as a rare side effect, but no regulatory claims of general sedation are present.

---

Q: Can older adults or the elderly population use Амбробене safely?

Official documents do not specify the elderly as a restricted population. However, caution is advised for all individuals, regardless of age, who have severe renal (kidney) or hepatic (liver) impairment, as these conditions—which are often more prevalent in older adults—can affect how the body clears the medicine.

---

Q: Is there a known interaction between Амбробене and alcoholic beverages?

Official regulatory documents typically do not list a formal, drug-specific interaction with alcohol. However, official guidance sometimes notes that alcohol may irritate the stomach lining or worsen existing side effects.

---

Q: Does taking Амбробене with or after food change its effectiveness?

Regulatory labels clearly specify that all oral forms of the medicine must be taken after meals. However, official interaction data generally indicates that co-administration with food is not considered clinically significant in terms of altering the drug's effectiveness.

---

Q: Is the syrup form of Амбробене suitable for adults as well as children?

Yes, the syrup or oral solution formulation is indicated for use by adults, adolescents, and children over 2 years of age. The specific volume of the dose, however, will differ according to the patient’s age group.

---

Q: Why is Амбробене sometimes not recommended for very young children (e.g., under 2 years)?

Official product information specifies that use in children under 2 years of age is generally contraindicated (officially restricted in regulatory labeling). This restriction is primarily based on the lack of established safety and efficacy data for this very young age group, who have immature organ function.

---

Q: Does Амбробене contain sugar or is there an option for people with diabetes?

The liquid forms of the medicine can vary in their composition and may contain excipients like sugar, glycerol, or sorbitol. Due to the potential presence of these ingredients, regulatory labeling emphasizes the need to check the specific formulation’s ingredients listed in the product leaflet, especially for patients with diabetes or Hereditary Fructose Intolerance.

---

Q: Is it required to shake the bottle before using the Амбробене syrup formulation?

Instructions for the proper use of the syrup or oral solution formulation often include a direction to shake the bottle well before measuring and consuming the dose.

---

Q: Can the effectiveness of Амбробене be reduced by taking certain vitamins or supplements?

Official documents generally advise patients to inform a healthcare provider about all concomitant medicines, including nutritional supplements or herbal products. This is because their potential for interaction with Ambroxol may not always be documented in official regulatory materials.

---

Q: Is it normal to notice an increase in mucus after starting Амбробене?

Yes, this may be observed. The drug’s function as a secretolytic is to increase the volume and decrease the viscosity of bronchial secretions. This action helps to mobilize the phlegm, which can result in a perceived increase in the amount of mucus being coughed up.

---

Q: Is there a risk of becoming dependent on Амбробене (habit-forming concern)?

Official regulatory documents do not describe Ambroxol as a substance with known dependency or habit-forming potential.

---

Q: Is there evidence to support the use of Амбробене in chronic lung conditions?

Yes, regulatory documents indicate that Ambroxol is typically used in the treatment of both acute and chronic obstructive respiratory diseases. This includes conditions like chronic bronchitis and bronchiectasis that are associated with excessive mucus and phlegm production.

How to Store and Dispose of Ambrobene (Ambroxol Hydrochloride)

The official regulatory documents specify strict conditions for storing and disposing of Ambrobene to maintain product stability and safety.

Official Storage Requirements

Storage Parameter	Regulatory Requirement
Maximum Temperature	Store at temperatures not exceeding 30 C
Child Safety	Keep out of the sight and reach of children
Protection	Keep container tightly sealed and protected from light

For liquid forms, specific product licenses mandate use within 1 to 6 months after the first opening. Disposal of unused or expired medicine must not be via household waste or wastewater. Consult a pharmacist or local authority for directions on discarding the product in accordance with local environmental regulations.